

Effects of Transfection on Metastatic Potential of Mouse 3T3 Cells

INTRODUCTION

About 1,500 people die every day from cancer, thus emphasizing the importance of further cancer research and in-depth explorations of cancer treatment plans (Seyfried and Hysentruyt, 2014).

What is metastasis and how does it relate to this project? Metastasis is the "process by which cancer cells spread to other parts of the body" (National Cancer Institution). By transfecting the cells (knocking down the p53 and Myosin Heavy Chain 9 genes in Mouse 3T3 cells), I hope to decrease the metastatic potential, the likelyhood of the cancer cells to spread, of the cells.

What are the p53 and Myosin Heavy Chain 9 genes? The p53 gene behaves as a tumor suppressor gene; the Myosin Heavy Chain 9 controls cell growth, especially during the cytokinesis stage.

Landmark Experiment: Scientists wanted to see how mutations in proto-oncogenes cause cancer in the lymphatic system. This research showed that "somatic hypermutations in tumor suppressor genes involved in major human malignancies offer a novel insight in cancer development, progression and spread" (Kashuba, 2009). This landmark case revealed that many cancer or metastasis cases involve mutations in the proto-oncogenes or tumor suppressors genes, like p53.

DISCUSSION, ANALYSIS, AND EVALUATION


Research Question: How does the transfection of the p53 and MYH9 genes in Mouse 3T3 cells affect the metastatic potential of the cells?

Significance of Results


Figure 3 implies that if p53 and MYH9 are knocked down, more cells migrate toward the other chamber. Thus, this

emphasizes the importance of the p53 and MYH9 genes in controlling cell growth and cell migration.

The lower the ratio between serum-present and serum-absent plates signifies that cell migration is lower, and that metastatic potential is lower. Therefore, when the cells were transfected and p53 and MYH9 were knocked down, the metastatic potential increased, as 2.463 and 2.751 is significantly larger than the Wild Type's 2.342 ratio.



¹Ananya Murali and ²Victoria Wang ¹Henry M. Gunn High School, ²University of California San Francisco



RESEARCH METHODOLOGIES

ACKNOWLEDGEMENTS / REFERENCES

I would like to thank my mentor, Ms. Victoria Wang, for assisting me throughout this project. Her constant mentorship encouraged me to think outside the box and improve my lab techniques. I would also like to extend my thanks to my teacher, Ms. Merchant, who thoroughly guided me through the writing portion of the project and gave me tips on how I should go about experimenting.

Works Cited:


Metastatic Cancer. (n.d.). Retrieved January 11, 2018, from https://www.cancer.gov/types/metastatic-cancer


Seyfried, T. N., & Huysentruyt, L. C. (2013). On the Origin of Cancer Metastasis. Critical Reviews TM in Oncogenesis, 18(1 - 2), 43-73. doi:10.1615/critrevoncog.v18.i1-2.40

Vladimir Kashuba-Tatiana Pavlova-Elvira Grigorieva-Alexey Kutsenko-Surya Yenamandra-Jingfeng Li-Fuli Wang-Alexei Protopopov-Veronika Zabarovska-Vera Senchenko-Klas Haraldson-Tatiana Eshchenko-Julia Kobliakova-Olga Vorontsova-Igor Kuzmin-Eleonora Braga-Vladimir Blinov-Lev Kisselev-Yi-Xin Zeng-Ingemar Ernberg-Michael Lerman-George Klein-Eugene Zabarovsky - http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0005231

DATA AND FINDINGS

Figure 3: The graph shows the ratios of serum-present over serum-absent trials for each of the different plates (WT, p53 knockdown, and MYH9 knockdown). Each of the plates had two trails, and the serum-present and absent values were found by taking the average of the two values.*






- Equipment used: \succ Serum-free media and Serum-present media \succ Mouse 3T3 cells
 - (standard fibroblast cell line)
- Types of Mouse 3T3 cells:
- \succ Wild Type cells (no transfection)
- > Myosin Heavy Chain 9 knockdown cells (transfected cells)
- > p53 knockdown cells (transfected cells)



CONCLUSIONS, IMPLICATIONS, AND NEXT STEPS





*The different plates were WT

- serum-present, WT serum-absent, p53
- knockdown serum-present, p53 knockdown
- serum-absent, MYH9 knockdown
- serum-present, and MYH9 serum-absent.

Noticing that the p53 and MYH9 genes have an effect on metastatic potential can emphasize that they are necessary in controlling cell growth. In fact, physicians can possibly enhance these genes to terminate metastases in future patients.

Figure 3 supports the fact that knocking down MYH9 (ratio of 2.751) has a much bigger impact on cell migration than knocking down p53 (mere 2.463 ratio). So, specifically working with enhancing the MYH9 protein may be beneficial, as it seems to have more of an influence on cell migration.